156 related articles for article (PubMed ID: 34260768)
1. Diarrhoea with the angiotensin receptor neprilysin inhibitor sacubitril + valsartan: A pharmacovigilance study.
Guion-Firmin J; Tessier S; Lepelley M; Faillie JL; Montastruc JL
Fundam Clin Pharmacol; 2022 Apr; 36(2):378-389. PubMed ID: 34260768
[TBL] [Abstract][Full Text] [Related]
2. Five Years of Sacubitril/Valsartan-a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance.
Kim YS; Brar S; D'Albo N; Dey A; Shah S; Ganatra S; Dani SS
Cardiovasc Drugs Ther; 2022 Oct; 36(5):915-924. PubMed ID: 34125356
[TBL] [Abstract][Full Text] [Related]
3. Sacubitril/Valsartan (Entresto®)-Induced Hyponatremia.
Fuzaylova I; Lam C; Talreja O; Makaryus AN; Ahern D; Cassagnol M
J Pharm Pract; 2020 Oct; 33(5):696-699. PubMed ID: 30776953
[TBL] [Abstract][Full Text] [Related]
4. The real-world safety of sacubitril / valsartan among older adults (≥75): A pharmacovigilance study from the FDA data.
Lerman TT; Greenberg N; Fishman B; Goldman A; Talmor-Barkan Y; Bauer M; Goldberg I; Goldberg E; Kornowski R; Krause I; Levi A; Cohen E
Int J Cardiol; 2024 Feb; 397():131613. PubMed ID: 38030039
[TBL] [Abstract][Full Text] [Related]
5. Updated insights on dementia-related risk of sacubitril/valsartan: A real-world pharmacovigilance analysis.
Chen C; Ding L; Fu F; Xiao J
CNS Neurosci Ther; 2023 Sep; 29(9):2548-2554. PubMed ID: 36971193
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV
JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
[TBL] [Abstract][Full Text] [Related]
7. Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system.
Gatti M; Antonazzo IC; Diemberger I; De Ponti F; Raschi E
Eur J Prev Cardiol; 2021 Aug; 28(9):983-989. PubMed ID: 34402868
[TBL] [Abstract][Full Text] [Related]
8. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
Hubers SA; Brown NJ
Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
[TBL] [Abstract][Full Text] [Related]
9. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.
Solomon SD; McMurray JJV; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Claggett B; Jhund PS; Boytsov SA; Comin-Colet J; Cleland J; Düngen HD; Goncalvesova E; Katova T; Kerr Saraiva JF; Lelonek M; Merkely B; Senni M; Shah SJ; Zhou J; Rizkala AR; Gong J; Shi VC; Lefkowitz MP;
N Engl J Med; 2019 Oct; 381(17):1609-1620. PubMed ID: 31475794
[TBL] [Abstract][Full Text] [Related]
11. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan.
Jhund PS; McMurray JJ
Heart; 2016 Sep; 102(17):1342-7. PubMed ID: 27207980
[TBL] [Abstract][Full Text] [Related]
12. Different Doses of Sacubitril/Valsartan Compared with Olmesartan in Patients with Essential Hypertension: A Systematic Review and Meta-Analysis.
Almarjan AI; Almarjan SA; Masoud AT
High Blood Press Cardiovasc Prev; 2023 May; 30(3):207-218. PubMed ID: 37017901
[TBL] [Abstract][Full Text] [Related]
13. Cognition- and Dementia-Related Adverse Effects With Sacubitril-Valsartan: Analysis of the FDA Adverse Event Report System Database.
Perlman A; Hirsh Raccah B; Matok I; Muszkat M
J Card Fail; 2018 Aug; 24(8):533-536. PubMed ID: 29746915
[TBL] [Abstract][Full Text] [Related]
14. Acute Tubular Necrosis Associated with Angiotensin Receptor-neprilysin Inhibitor.
Kim MJ; Jang HN; Song HN; Lee JS; Kang MG
Intern Med; 2022 May; 61(10):1573-1576. PubMed ID: 34707049
[TBL] [Abstract][Full Text] [Related]
15. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
[TBL] [Abstract][Full Text] [Related]
16. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
Böhm M; Young R; Jhund PS; Solomon SD; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Packer M; McMurray JJV
Eur Heart J; 2017 Apr; 38(15):1132-1143. PubMed ID: 28158398
[TBL] [Abstract][Full Text] [Related]
17. Neprilysin inhibition with sacubitril/valsartan in the treatment of heart failure: mortality bang for your buck.
Ansara AJ; Kolanczyk DM; Koehler JM
J Clin Pharm Ther; 2016 Apr; 41(2):119-27. PubMed ID: 26992459
[TBL] [Abstract][Full Text] [Related]
18. Angioedema with sacubitril/valsartan: Trial-level meta-analysis of over 14,000 patients and real-world evidence to date.
Dani SS; Ganatra S; Vaduganathan M
Int J Cardiol; 2021 Jan; 323():188-191. PubMed ID: 32841619
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of sacubitril/valsartan versus aldosterone antagonists in heart failure with reduced ejection fraction: A retrospective cohort study.
Riaz M; Smith SM; Dietrich EA; Pepine CJ; Park H
Pharmacotherapy; 2021 Sep; 41(9):710-721. PubMed ID: 34170559
[TBL] [Abstract][Full Text] [Related]
20. Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor.
Dargad RR; Prajapati MR; Dargad RR; Parekh JD
Indian Heart J; 2018 Jul; 70 Suppl 1(Suppl 1):S102-S110. PubMed ID: 30122239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
